Nascent Pharma Holdings is focused on maximizing the value of its cannabis patent portfolios, with patents valued at $122,000,000 in 2020 by an independent valuation firm. The name and symbol change follow the holding company reorganization completed in October 2024. The company operates as a penny stock on OTC markets with minimal current revenue and significant operating losses.
Cyborg Score Rationale
In 2023, revenue was $2.16 million (down 67.76% from $6.69 million in 2022) with losses of $9.74 million. The company trades at $0.01 per share with a market cap of $1.92M as of June 2026. High execution risk exists in monetizing cannabis patents amid regulatory uncertainty.
Top Insights
Patented uses include treating cancer, IBS, chronic pain, PTSD, anxiety, sleep disorders, and opioid dependencies; the company plans to pursue opportunities to license and develop uses for these patents.
Revenue collapsed 67.76% year-over-year in 2023 to $2.16M while losses reached $9.74M, indicating severe operational challenges.
Company rebranded from Can B Corp. to Nascent Pharma Holdings, Inc. and changed ticker from CANB to NASC, effective September 16, 2025.
Stock trades at penny-stock levels ($0.01) on OTC Pink Limited tier with minimal liquidity and high volatility risk.
Named Competitors
Exhemplary Life — Hemp and CBD wellness products
Better Health First — Health and wellness products
Gruene Botanicals — Botanical wellness products
Recent Developments
(September 2025) Completed name change from Can B Corp. to Nascent Pharma Holdings, Inc. and ticker change to NASC
(October 2024) Completed holding company reorganization with Nascent Pharma Holdings becoming parent company
(October 2023) Consolidated Pure Health Products operations from Lacey, WA to Colorado
Open the full interactive Nascent Pharma Holdings, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.